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Abstract: The neurotoxic non-protein amino acid, β-N-methylamino-L-alanine (BMAA), 
was first associated with the high incidence of Amyotrophic Lateral Sclerosis/Parkinsonism 
Dementia Complex (ALS/PDC) in Guam. Recently, BMAA has been implicated as a fierce 
environmental factor that contributes to the etiology of Alzheimer’s and Parkinson’s diseases, 
in addition to ALS. However, the toxicity of BMAA in vivo has not been clearly 
demonstrated. Here we report our investigation of the neurotoxicity of BMAA in Drosophila. 
We found that dietary intake of BMAA reduced life span, locomotor functions, and learning 
and memory abilities in flies. The severity of the alterations in phenotype is correlated with 
the concentration of BMAA detected in flies. Interestingly, developmental exposure to 
BMAA had limited impact on survival rate, but reduced fertility in females, and caused 
delayed neurological impairment in aged adults. Our studies indicate that BMAA exposure 
causes chronic neurotoxicity, and that Drosophila serves as a useful model in dissecting the 
pathogenesis of ALS/PDC. 
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1. Introduction 
Alzheimer’s and Parkinson’s diseases and Amyotrophic Lateral Sclerosis (ALS) are the most 
common age-related neurodegenerative diseases worldwide. Most cases (90–95%) of these diseases 
are sporadic and have essentially no known genetic component. Previous cytotoxic studies flourished 
the awareness of high ALS incidence on the South Pacific island of Guam and in conjunction with 
dietary epidemiological observations, these studies have allowed for the isolation of a potential 
neurotoxin,  β-N-methylamino-l-alanine (BMAA) [1,2]. BMAA is a neurotoxic, non-lipophilic,   
non-protein amino acid produced by cyanobacteria. In the Guam ecosystem BMAA is produced by 
cyanobacteria of the genus Nostoc, which are root symbionts of cycads, and is then biomagnified in 
cycad seeds and in Marianas flying foxes (Pteropus mariannus) that forage on them [3]. Consumption 
of flying foxes by the Chamorro people has been implicated as a delivery mechanism for relatively 
high doses of BMAA in the Chamorro diet [1]. BMAA occurs not only as a free amino acid in the 
ecosystem but also can be released from a protein-bound form by acid hydrolysis [4]. BMAA has been 
detected in both free and protein-bound form in the brain tissues of Chamorro patients who died from 
ALS/PDC [4]. 
Significantly, BMAA is not restricted to Guam but is rather broadly present in the environment. 
High concentrations of BMAA have been found to be associated with cyanobacterial blooms outside 
of Guam, in marine [5] and fresh water [6] environments. Recently, the occurrence and 
bioaccumulation of BMAA was detected in a temperate aquatic ecosystem (Baltic Sea), suggesting a 
potential widespread human exposure [7]. It is interesting to note that different forms of cyanobacteria 
are used as dietary items in several indigenous cultures around the world, and recently BMAA was 
detected in llullucha, which are colonies of cyanobacteria consumed by Peruvian highlanders [8]. The 
health effects of these foods remain to be examined. Evidence supporting the global presence of 
BMAA and the biomagnification of cyanobacterial BMAA came from recent studies that reported 
detection of BMAA in brain tissue from ALS, Parkinson’s disease (PD) and Alzheimer’s disease (AD) 
patients in the United States and Canada, whereas no or very low levels of BMAA were detected in 
brain tissue from subjects without clinical or pathological evidence of ALS or AD and in other ALS 
patient series [9–13]. The significant concentration of BMAA in selected human disease patients 
outside Guam suggests the existence of alternative ecological pathways for the bioaccumulation of 
BMAA in aquatic or terrestrial ecosystems in continental America, and more importantly a possible 
role of BMAA in the pathogenesis of multiple neurodegenerative diseases. These observations imply 
that BMAA could be one of the first environmental factors that contribute to the etiology of AD,  
PD and ALS. 
BMAA is a non-protein amino acid that structurally appears as a methylated alanine. Several 
studies using cultured neurons have indicated that BMAA induced neuronal cell death  [14] and 
preferentially injured spinal motor neurons in vitro [15]. Inasmuch as the carbamate modification of 
BMAA under physiological conditions in the presence of bicarbonate structurally resembles 
glutamate  [16], it has been postulated that BMAA may act as an agonist for AMPA/kainite 
receptors  [15], NMDA and mGluR5 receptors  [14], or may mediate neurodegeneration via an 
excitotoxic mechanism induced by the activation of excitatory amino acid (EAA) receptors  [17]. 
However, most of these studies have been done on cultured brain cells, and the toxicity of BMAA Toxins 2010, 2  
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in vivo has not been demonstrated clearly and remains a controversial issue [18]. Furthermore, it is 
unknown what concentration of BMAA is toxic or detrimental and whether the concentration of 
BMAA in the brain is correlated with neurodegeneration. The BMAA toxicology field has reached the 
stage where the development of animal models is crucial [19]. To address these questions we used a 
recently established BMAA feeding paradigm in fruit fly Drosophila melanogaster [20] to examine 
the toxicity of BMAA on survival and neurological functions. Here, we report our findings that dietary 
intake of BMAA reduced the life span as well as the locomotor abilities and learning and memory 
functions of Drosophila. We have also found that the severity of the alterations in phenotype was 
proportional to the concentration of BMAA in the feeding medium and was correlated with the 
presence of free BMAA in the fly brain. Furthermore, the findings in this work show that BMAA 
feeding during development had a limited impact on the survival rate or the progress of development; 
but resulted in reduced fertility in females and caused delayed neurological impairment in aged adults. 
Together, these results provide the first experimental evidence for progressive neurotoxicity of 
BMAA. In summary, the Drosophila model allowed us to evaluate the neurotoxicity of BMAA in vivo, 
and our results here provide a link between the neurological deficits and the concentrations of free 
BMAA in the nervous system. 
2. Materials and Methods 
2.1. Drosophila Culture and Drug Feeding 
Wild-type Canton S (CS) flies were raised on corn meal/yeast/molasses media at room temperature 
(20 °C) under ambient light. For BMAA and other amino acid feeding experiments, BMAA, Glutamic 
acid or Alanine (B107, G1251 or A7627, Sigma-Aldrich, St. Louis, U.S.) were dissolved in water and 
mixed into sucrose/agar medium. The final concentration of the medium was 5% sucrose, 1% agar,  
and 4 mM of amino acid. CS male and female flies 1–3 days in age were separated, and twenty flies 
were put into each vial containing 2 mL sucrose/agar medium. The numbers of dead and live flies were 
recorded daily. Dead flies were distinguished by counting the number of flies that remained inanimate 
for over 15 seconds after a shaking of the vial. About 200–300 flies were used for each experimental 
group. The amino acid-containing medium was replaced once a week. 
2.2. Negative Geotaxic Assay 
The negative geotaxis assay (climbing assay) was performed as described [21,22]. Flies were sexed 
and placed in empty polystyrene vials in groups of ten and allowed 10 minutes to acclimatize. In the 
behavior assay, flies were gently tapped to the bottom of the vial and then allowed to crawl. In 
response to tapping (gentle agitation), flies crawl/climb upward against gravity. The number of flies 
passing 8 cm within 10 seconds was counted. Ten trials were performed for each group. Ten to twenty 
groups (100 to 200 flies) were tested for each experimental condition. Only viable flies were used in 
climbing assays, and after each assay, the viability of flies was retested. Any flies that died during the 
course of the assay were eliminated and the data points associated with dead flies were disregarded. Toxins 2010, 2  
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2.3. Aversive Phototaxic Suppression Assay 
The aversive phototaxic suppression assay measures the learning and memory ability of flies. It was 
carried out as described [23,24] with a modified T-maze where the maze chamber was connected with 
two horizontal vials—a darkened vial externally covered by foil paper and a lighted vial connected to a 
light source. Filter paper soaked with 400 μL of a 1 µM quinine hydrochloride solution was placed in 
the lighted vial. Wild-type (Canton S) female flies 1–3 days old were fed with control 1% sugar/5% 
sucrose media or 1% sugar/5% sucrose media with 4mM L-BMAA, glutamate or alanine for three 
days. On day four, these female flies were subjected to the aversive phototaxic suppression assay. The 
assay was divided into two phases, a conditioning phase and a test phase. For conditioning, a fly was 
placed in the darkened vial and given a 30 second acclimatization period. Then the trap door that 
divides both vials was opened so that the fly could cross toward the lighted vial. The fly was then  
given 25 seconds to cross to the lighted vial. Any fly that showed any locomotor or phototactic defects 
and did not cross over to the lighted vial within 25 seconds in the first conditioning trial was discarded. 
At the end of this (25 second) time period, the light was turned off, and the fly was quickly and gently 
tapped back into the darkened vial followed by closing the trap door. After 15 seconds of 
acclimatization in the darkened vial, the light was turned on and the trap door was opened. The fly was 
given 25 seconds to cross over to the lighted vial. This process was repeated ten times to complete the 
conditioning phase. Five test trials were performed immediately post-conditioning (testing learning 
abilities), and six hours post-conditioning (testing memory abilities). A pass response was one where 
the fly refused to cross toward the lighted vial and a fail response was one where the fly entered into 
the lighted vial. The number of pass responses was recorded and the success rate was calculated for 
each fly. Learning and memory index for each treatment group was plotted as the mean of the success 
rate of the qualified flies that completed the conditioning phase. Forty to fifty flies from each group 
were collected and subjected to the test and twenty to twenty five flies that completed the conditioning 
phase were included. 
2.4. Tissue Sample Preparation for HPLC 
The tissue preparation procedure was optimized for fly tissue based on a previously described 
sample preparation protocol for cyanobacteria extraction  [5,20]. Adult flies were anesthetized by 
carbon dioxide, collected into eppendorf tubes and flash-frozen to −80 °C. For extraction 450 µL  
of 70% methanol was added and lysis was achieved by three freeze-thaw cycles in liquid nitrogen, 
followed by three cycles of sonication for 20 seconds (Branson Sonifier 150). Samples were kept on 
ice to minimize protein degradation. Samples were then dried by centrifugal vacuum concentration  
at 4 °C. The dry weight of samples was measured and recorded. The dried material was then 
resuspended in 250 µL of 70% methanol, and 4 volumes (1 mL) of acetone, kept at −20 °C, was added. 
The proteins were precipitated at −20 °C
 for a minimum of three hours and centrifuged for 20 minutes 
at 4 °C
 at 15000xg. The supernatant containing free amino acids was collected and filtered with an 
Amicon spin-filter (Millipore, UFC30GV00). The protein pellet containing bound amino acids was 
hydrolyzed in 500 µL 6M HCl in closed glass vials at 110 °C
 for 24 hours, filtered with an Amicon 
spin-filter (Millipore), and dried overnight at 55 °C. The sample was then resuspended in 110 µL  
of 20 mM HCl. Toxins 2010, 2  
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2.5. Detection of BMAA with HPLC Analysis 
A fluorescence detection method for BMAA was used as described previously [20]. The detection 
limit of L-BMAA in fly tissue is 4 ng BMAA/1.6 µg sample [20]. The samples were diluted and 
derivatized with 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate (Waters AQC Tag reagent, 
WAT052880) at a concentration of 20% AQC tag in 0.5 M borate buffer. 
The HPLC system (Waters, U.S.) used in this study consisted of a binary HPLC pump 
(Waters  1525), an autosampler (Waters 717), and a scanning fluorescence detector (Waters 474). 
Separation of amino acids was carried out using a Nova-Pak C18 Column (4 µm, 3.9 × 300 mm, 
Waters, WAT 011695), joined with a Nova-Pak®C18 Guard Column (4 µm, 3.9 × 20 mm, 
WAT044380). The column was thermostated at 37 °C. The flow rate was set to 1.0 mL/min and the 
injection volume was 10 µL. The excitation and emission peak wavelengths for fluorescence detection 
of derivatized BMAA were 250 nm and 395 nm. Mobile phase A consisted of a dilution 1:11 of  
Eluent A concentrate (WAT052890) set to pH 5.2 prepared with HPLC grade water (VWR 4218-03). 
Eluent B consisted of 52% HPLC grade acetonitrile (Sigma 34851) and 48% HPLC grade water. 
Gradient conditions were as described  [5]. The HPLC chromatographs were acquired and then 
analyzed by Empower II software (Waters). 
3. Results 
3.1. Dietary Intake of BMAA Reduced Life Span and Induced Locomotor and Learning and Memory 
Deficits in a Dose-dependent Manner 
The fruit fly Drosophila has been used to study human neurodegenerative diseases, including ALS, 
and these studies have contributed greatly to our understanding of the mechanisms of 
neurodegeneration [25–28]. Specifically, Drosophila has been shown to be an ideal model to 
quantitatively measure motor coordination and learning and memory, as flies have distinctive 
behaviors that are stereotypic and quantifiable [29], such as geotaxic and phototaxic behavior [30,31]. 
Geotaxis refers to the climbing behavior of flies and their natural tendency to climb against gravity, 
where a reduced climbing behavior indicates reduced motor coordination [21,22]. Phototaxis refers to 
the instinctive behavior of flies to move toward light [32]. 
To investigate the toxicity of BMAA on adult flies, we first measured the effects of dietary intake 
of BMAA on life span. Adult flies of 1–3 days of age were raised on sucrose/agar media containing  
0, 2, 4, 6, 8 or 10 mM of BMAA. Because BMAA is structurally similar to alanine in its native form 
and to glutamate in its carbamate form [16], we included alanine and glutamate as controls. As shown 
in Figure 1, BMAA severely reduced the life span of both male and female flies in a dose-dependent 
manner (Figure 1A and 1B). Glutamate also reduced life span, but to a lesser extent (Figure 1C and 1D), 
and alanine had no effect on the life span of adult flies (Figure 1E and 1F). Overall, males were more 
susceptible to BMAA as the survival rate of males at each dosage was lower than that of females. 
Next we examined the effects of BMAA on geotaxic behavior. We measured the climbing 
performance of viable flies at day seven of BMAA feeding, as this time point marked a survival rate  
of 50% or higher at all concentrations (Figure 1). As shown in Figure 2A, BMAA reduced the 
climbing performance in a dose-dependent manner. Interestingly, male flies were more susceptible to Toxins 2010, 2  
 
 
2668
BMAA, as 2 mM BMAA significantly reduced the climbing performance in male flies, but not in 
females. No successful climbing behavior was observed in flies fed with 8 or 10 mM of BMAA 
(Figure 2A and data not shown). Compared to glutamate and alanine at 4 mM, only BMAA affected 
the geotaxic behavior (Figure 2B), indicating the specific neurotoxicity mediated by BMAA. 
Figure 1. BMAA severely reduced the life span of Drosophila melanogaster in a 
dose-dependent manner. Adult flies from 1–3 days old were collected, separated as males 
and females, and raised on a medium consisting of 5% sugar, 1% agar and 0 to 10 mM of 
BMAA, glutamate or alanine. About 200 flies were tested in each treatment group. The 
numbers of live and dead flies were recorded daily, and the survival rate was calculated 
and plotted. Represented panels show the survival curves of male and female flies raised 
on medium containing BMAA (A, B), glutamate (C, D) and alanine (E, F). 
 Toxins 2010, 2  
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Figure 2. BMAA reduced geotactic behavior and learning and memory abilities. (A-B) 
Climbing tests were done on adult flies fed on sugar/agar medium containing BMAA, 
glutamate, or alanine for 7 days. The climbing performance was calculated by the percentage 
of flies that passed 8 cm within a ten second period. (A) Climbing performance of adult flies 
fed with 0 to 8 mM BMAA. (B) Climbing performance of adult flies fed with 4 mM BMAA, 
glutamate or alanine. At least 200 flies were tested for each group. All data were presented as 
mean ± S.E.M. n = 10. (C) The aversive phototaxic suppression assay was done on adult 
female flies that fed on sugar/agar medium containing BMAA, glutamate, or alanine   
for 3 days. The learning and memory index was calculated by the success rate of flies that 
avoided the lighted chamber containing quinine within 25 seconds during the testing phase of 
the assay. Forty to 50 flies from each group were collected and subjected to the test and at 
least 20 flies that completed the conditioning phase were included for each group. All data 
were presented as mean ± S.E.M. n ≥ 20. Significance level was established by one way 
ANOVA post-hoc Scheffe test. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. 
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In order to test the specific effects of BMAA on central nervous system function, we examined the 
learning and memory abilities of flies upon BMAA treatment using the aversive phototaxic 
suppression assay  [23,24]. Flies are instinctively phototaxic  [32], but quinine, on the other hand, 
induces avoidance behavior and is frequently used as a negative reinforcer [33–36]. In the aversive 
phototaxic suppression assay, flies were individually placed into a T-maze and allowed to choose 
between a lighted and a darkened chamber. Filter paper is soaked with quinine solution and placed into 
the lighted chamber such that the quinine provided an aversive association. During the conditioning 
phase, flies learn to suppress their instinctively phototaxic behavior in order to avoid quinine. Test 
trials performed immediately post-conditioning (0 hr PC) showed their learning abilities while the test 
trials performed six hours post-conditioning (6 hr PC) showed their memory abilities. Because this 
assay requires intact motor ability, we tested the learning and memory ability of flies after three days 
of feeding with 4 mM BMAA, glutamate or alanine, as this time point marked a climbing pass rate of 
BMAA-treated flies at around 50% of the control group (data not shown). As shown in Figure 2C, 
BMAA significantly reduced both learning and memory abilities. Feeding with 4 mM glutamate also 
significantly reduced the learning ability (0 hr PC), although to a lesser extent compared to BMAA. 
The memory ability of flies (6 hr PC) fed with glutamate was also reduced, although not as 
significantly (p = 0.061, one way ANOVA post-hoc Scheffe test). Alanine did not reduce learning and 
memory abilities by a significant level (p ≥ 0.1 and p ≥ 0.5 respectively, one way ANOVA post-hoc 
Scheffe test). These results suggest that BMAA induces learning and memory impairment. Glutamate 
also reduced learning ability, but the effect is much less profound than BMAA. 
3.2. Dose-dependent Accumulation of BMAA in Flies 
In order to quantitatively measure the concentration of BMAA in flies after dietary intake and the 
incorporation of BMAA into fly tissues, we developed an HPLC detection method for Drosophila 
matrix [20], adapted from the previously established method for cyanobacteria [5]. BMAA and the 
protein amino acids were separated by reverse-phase elution, and the BMAA concentration was 
determined by detection of the AQC fluorescent tag. The free BMAA fraction is present in the 
supernatant of tissue extracts, and the protein-bound BMAA fraction is present in the pellet of tissue 
extracts. Because of the difference in amino acid concentration in the supernatant (free amino acid 
fraction) and in the pellet (protein-bound fraction), we developed different derivatization methods to 
achieve optimal detection of free and protein-bound BMAA  [20]. Each sample was run with and 
without a pure BMAA spike to allow the accurate detection of BMAA. As shown in Figure 3A   
and 3B, overlaying chromatograms from sample runs with and without a BMAA spike revealed 
BMAA in flies fed with 8 mM BMAA, while no BMAA peak was detected in control flies (0 mM 
treatment group). The chromatographic peak of BMAA is consistent with previously published results 
in cycads, flying foxes and ALS/PDC patients  [5,8,10,11]. Using this HPLC method we have 
measured the concentration of free and protein-bound BMAA in flies and found a dose-dependent 
increase of BMAA concentration in both males and females fed with various concentrations of BMAA 
for seven days (Figure 3C). Interestingly, we detected higher levels of BMAA in the free fraction than 
in the bound fraction in both males and females, with 1198 ± 287 µg/g free BMAA and 618 ± 78 µg/g 
bound BMAA in male flies fed with 8 mM BMAA. The level of free BMAA is lower than that Toxins 2010, 2  
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detected in flying foxes (3554 µg/g)—the highest level of free BMAA reported so far—and the level 
of bound BMAA is similar to that detected in Chamorro people with ALS/PDC (627 µg/g) [4,10]. To 
examine whether BMAA is incorporated into the brain, we separated the fly heads from the bodies and 
measured the concentration of BMAA in the heads and bodies separately. Drosophila heads consist of 
head cuticle, eyes, antenna, proboscis, and the brain inside. Since the non-nervous system tissue 
including the cuticle and a small amount of muscle cells in the proboscis, is a small part of the whole 
head, and the majority of the head is nervous system tissue, measuring BMAA concentration in the 
heads would be a good indication of the incorporation of BMAA into the central nervous system. As 
shown in Figure 3 we detected both free- and protein-bound BMAA in the body (Figure 3D and 3E). 
However, we only detected free BMAA in the head (Figure 3F). These results suggest that the 
Drosophila feeding model recapitulates the accumulation of BMAA in the Guam ecosystem and the 
incorporation of BMAA into the brain. More importantly, the dose-dependent increase of BMAA 
concentration in flies is correlated with the severity of alterations in the phenotype. Our observation of 
preferential brain accumulation therefore might explain the neurodegeneration in the central nervous 
system of Guam ALS/PDC and other neurodegenerative diseases that might be caused by or related to 
BMAA exposure [11,37]. 
Figure 3. Accumulation of free and protein-bound BMAA in adult flies. Adult flies raised 
on 0 to 8 mM BMAA for 7 days were collected and extracted for HPLC detection of free 
and protein-bound BMAA. (A, B) Representative HPLC chromatographic analysis of 
control sample (A) overlain with a BMAA spike, and treatment (8 mM) sample (B) 
overlain with a BMAA spike. In whole fly extracts both free and protein-bound BMAA 
were detected in male and female flies (C). When flies were separated into body and head 
fractions, it is noteworthy that protein-bound BMAA was found in the body extract (D) but 
not in the head extract. Free BMAA was detected in both body (E) and head extracts (F). 
All data were presented as mean ± S.E.M. n = 3. 
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Figure 3. Cont. 
 
3.3. Developmental Exposure to BMAA Induces Delayed Locomotor Deficits in Aged Flies 
Exposure to BMAA during adult stages reduced the life span of Drosophila and impaired the 
Drosophila nervous system. To examine the impact of BMAA on development, we collected embryos 
and raised them on medium containing 4 mM BMAA, alanine or glutamate. The number of surviving 
flies was recorded at the developmental stages of first instar (L1), third instar (L3), pupa and adult. As 
shown in Figure 4A, BMAA slightly reduced the survival rate at the pupa and adult stage, while 
alanine had no effect. Interestingly, glutamate severely reduced the survival rate to 50% at the adult 
stage (Figure 4A), suggesting that glutamate has more developmental toxicity than BMAA. To 
examine the effect of early developmental BMAA exposure on adult neurological functions, we 
collected flies eclosed from larvae fed with BMAA during development and served normal food, and 
measured their life span and geotactic behavior at 7, 14 and 21 days. Although the life span of adult 
flies with developmental BMAA exposure was not significantly reduced (Figure 4B), their geotactic 
behavior was significantly impaired. As shown in Figure 4C, flies with developmental BMAA 
exposure showed significant reduction in climbing performance at all ages, in contrast to flies exposed 
to alanine or glutamate, suggesting that developmental exposure to BMAA has a delayed effect on 
neurological behavior in the adult stages. Next we measured the concentration of BMAA in third instar 
larvae and in adults eclosed from larvae fed with BMAA. In L3 larvae fed with 4 mM BMAA, we 
detected 475 ± 153 µg/g of free and 449 ± 94µg/g of protein-bound BMAA (Figure 4D), similar to the 
levels detected in adult flies fed with 4 mM BMAA (Figure 3C). Interestingly, in 7 day-old adult flies 
eclosed from BMAA-fed larvae, we detected 215 ± 70 µg/g free BMAA and no protein-bound BMAA 
(Figure 4D), suggesting that protein-bound BMAA was reduced most likely through proteolysis and 
free BMAA was partially retained through metamorphosis and aging. Given the significant reduction 
in climbing performance we observed in 7 day-old flies (Figure 4C), it is possible that either free Toxins 2010, 2  
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BMAA may be the primary contributor to the decline in neurological behavior, or that protein-bound 
BMAA causes a long-lasting and delayed defect, impairing the nervous system after it has vanished. 
Figure 4. Developmental exposure of BMAA reduced survival rate and caused delayed 
locomotor deficits in aged flies. Fly embryos were collected and put on sucrose/agar/yeast 
medium containing 4 mM of BMAA, glutamate or alanine. The number of first instar (L1), 
third instar (L3) larvae, pupa and adult flies were recorded (A). The eclosed flies were then 
collected and raised on normal cornmeal/yeast/molasses food. Life span was recorded (B) 
and climbing performance was tested at 7, 14 and 21 days to examine the progressive 
degeneration furnished by BMAA (C). The amount of free or protein-bound BMAA was 
detected in both L3 larvae and adult flies (D). All data were presented as mean ± S.E.M. 
Significance level was established by t-test. * p ≤ 0.05, ** p ≤ 0.01. n ≥ 10. 
 
3.4. Developmental Exposure to BMAA Reduces Fertility in Female Flies 
To evaluate the impact of BMAA exposure on fertility and the health of progeny, we crossed the 
virgin females eclosed from larvae raised on either normal food (CS) or sucrose/agar medium 
containing 0 or 4 mM BMAA, with 1 day-old males from each group, and determined the number of 
progeny as well as the life span and neurological behavior of adult progeny. As shown in Figure 5A, 
females that were exposed to 4 mM BMAA produced significantly fewer progeny. However, males 
that were exposed to BMAA produced the same number of progeny, suggesting that BMAA exposure 
specifically reduces female fertility. To examine the possible vertical transmission of the toxicity of 
BMAA from exposed parents to progeny, we raised the progeny on normal food and measured their 
behavior and life span. The progeny showed no defects in geotactic behavior (Figure 5B) or life span 
(Figure 5C, male progeny and Figure 5D, female progeny). These results suggest that the toxicity of Toxins 2010, 2  
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BMAA was not carried into the progeny, indicating that BMAA did not have lasting effects on germ 
cells and there was no vertical transmission of the phenotype. 
Figure 5. Developmental exposure of BMAA reduced female fertility. Virgin females that 
eclosed from larvae raised on either normal cornmeal/yeast/molasses food (CS) or 
sucrose/agar/yeast medium containing 0 or 4 mM BMAA were crossed with 1 day-old 
males from each group. The crosses were maintained on normal cornmeal/yeast/molasses 
food. The number of eggs (both fertilized and unfertilized) produced from each cross was 
recorded daily for ten days, and the number of pupae and adult flies developed from 
embryos was also recorded (A). Climbing tests were performed on 7 day-old adult progeny 
from each cross (B). The life span of male (C) and female (D) adult progeny was also 
recorded. Significance level was determined with one way ANOVA followed by post hoc 
LSD test. * p ≤ 0.05. n ≥ 7. 
 
4. Discussions 
In this report we investigated the comprehensive toxicity of dietary intake of BMAA. We showed 
that BMAA shortens the life span, impairs locomotor function, and reduces learning and memory 
abilities in Drosophila. We further optimized an HPLC method to reliably detect both free and 
protein-bound BMAA in fly tissue extracts. We found that free BMAA is accumulated in the brain and 
that the severity of the phenotypes is correlated with the concentration of BMAA in flies. We also 
showed that developmental exposure of BMAA had a limited impact on the survival rate, but 
significantly reduced fertility in females and induced delayed neurological impairment in aged adults. Toxins 2010, 2  
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4.1. Toxic Levels of BMAA in Brain Tissue 
The reported detection of BMAA in brain tissue from ALS, PD and AD patients in the United 
States and Canada [9–13], and the ubiquity of cyanobacteria, support the global presence of BMAA. 
The potential threat of BMAA on global health necessitates a correlation of the level of BMAA in 
tissue and its toxicity, and an understanding of the tolerance level of BMAA by an organism. In our  
studies, the lowest level of BMAA detected in the brain that caused significant behavior defects   
is 221 ± 17 µg/g in males fed with food containing 2 mM BMAA. Females fed with the same food 
showed no significant behavior defects and 163 ± 28 µg/g BMAA was detected in the brain (Figures 2 
and 3). This observation suggests that BMAA levels of 200 µg/g in the brain might be sufficient to 
cause neurological defects. Importantly this observation is consistent with the range of BMAA 
detected in humans. For example, the amount of BMAA detected in postmodern brain tissue from 
ALS, PD and AD patients in the United States and Canada ranges from 111 to 218 µg/g while the 
highest level of BMAA detected in non-neurological disease control patients was 45 µg/g  [37]. 
Therefore, accumulation of BMAA in the brain above 100–200 µg/g is likely to increase the 
susceptibility to neurological diseases, although longer accumulation time in humans may allow even 
lower concentrations of BMAA to exert detrimental effects. 
4.2. Progressive Toxicity of BMAA 
One feature of Guam ALS/PDC is the prolonged incubation and wash-out periods, indicating that 
the responsible agent is a chronic neurotoxin [4]. Our results indicate that BMAA exposure has limited 
impact on development but causes delayed and progressive neurotoxicity. These studies are the first to 
recapitulate the progressive toxicity of BMAA exposure. Although the mechanisms underlying 
BMAA-protein interaction remain to be elucidated, it is possible that the ability of BMAA to be 
incorporated into protein and later released through catabolism extends the time window of its toxicity. 
It is likely that the protein-bound form of BMAA is less toxic but serves as sink for BMAA [4]. This 
might also partially explain the limited impact of BMAA exposure during development, as rapid 
growth and protein synthesis could incorporate BMAA into bound form and reduce the concentration 
of free BMAA. 
4.3. BMAA Has Stronger Toxicity than Glutamate 
BMAA forms carbamate in the presence of bicarbonate and is only neurotoxic in the presence of 
bicarbonate [16,38], suggesting that the carbamate is likely to be the toxic agent. Since carbamate 
BMAA is structurally similar to glutamate, it has been proposed that BMAA induces glutamatergic 
neurotoxic damage. Results from many studies using cultured mammalian neurons indicate that 
BMAA produces neurotoxicity by activation of glutamate receptors, and the effects of BMAA can be 
attenuated by antagonists of both NMDA and AMPA glutamate receptors [15,38–43]. In our studies, 
we observed more severe defects caused by BMAA in adult flies compared to glutamate at the same 
concentration, while glutamate had a higher impact on survival rate upon developmental exposure. 
These results suggest that glutamate has more acute toxicity than BMAA, and that BMAA may have 
other toxic effects in addition to glutamatergic neurotoxic damage. Several possibilities have emerged Toxins 2010, 2  
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from recent studies including increased oxidative stress mediated by BMAA inhibition of the 
cystine/glutamate antiporter Xc- system [44,45] and methylamine, a metabolite of BMAA that could 
cause oxidative stress and selective depletion of certain amino acids from intact brain cells [46,47]. 
Further studies are needed to understand the multiple mechanisms by which BMAA produces 
neurotoxicity. 
4. Conclusions 
Our results suggest that BMAA exposure causes chronic neurotoxicity in vivo. Our work also 
indicates that Drosophila is an excellent in vivo animal model to study BMAA-induced dementia and 
motor neuron degeneration. Recently, several Drosophila models of ALS have been established by 
expressing either mutant forms of SOD1 or ALS8/VAB [25–28]. Our work will serve as a basis for the 
next phase of research to uncover the mechanisms of BMAA-induced neurodegeneration, to reveal the 
interaction between environmental and genetic factors, and to identify targets for BMAA that mediate 
toxicity in motor neurons. 
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